Full Press Release Details
Accessibility: Skip TopNav
Summit Corporation PLC : Director/PDMR Shareholding
April 05, 2012 02:00 ET
Summit Therapeutics plc
Summit Therapeutics plc
Summit Corporation plc
('Summit' or 'the Company')
DIRECTOR AND PDMR SHARE DEALINGS
Oxford, UK, 5 April 2012, Summit (AIM: SUMM), a UK drug discovery company, has been notified that Mr Glyn Edwards, Chief Executive Officer of Summit, purchased 400,000 Ordinary Shares of 1 pence each at a price of 3.49 pence per share on 4 April 2012.
Mr Edwards now holds a total of 800,000 shares representing 0.43 per percent of the issued share capital. This figure excludes the Placing Shares Mr Edwards has subscribed for under the Placing announced by the Company yesterday.
Pursuant to the Placing, the Directors have agreed to subscribe for such number of Placing Shares as follows:
| Director | Number of Placing Shares |
| Barry Price | 400,000 |
| Stephen Davies | 500,000 |
| Andrew Richards | 200,000 |
| Glyn Edwards | 2,666,667 |
| Richard Storer | 200,000 |
For more information, please contact:
| Summit Glyn Edwards / Richard Pye | Tel: +44 (0)1235 443 939 |
| Singer Capital Markets (Nominated Adviser and Joint broker) Shaun Dobson / Claes Spång | Tel: +44 (0)203 205 7500 |
| Hybridan LLP (Joint broker) Claire Louise Noyce / Deepak Reddy | Tel: +44 (0)207 947 4350 |
| Peckwater PR (Financial public relations) Tarquin Edwards | Tel: +44 (0)7879 458 364 tarquin.edwards@peckwaterpr.co.uk |
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin(TM) technology platform for the discovery of new medicines and a portfolio of drug programme assets. Summit's programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.